Human Models of Selective Insulin Resistance: Alpelisib, Part I

Conditions: Insulin Resistance; Prediabetic State; Overweight and Obesity; Non-Alcoholic Fatty Liver Disease Interventions: Drug: Alpelisib 300 mg; Drug: Placebo; Drug: [1-13C] sodium acetate; Drug: [6,6-2H2] D-glucose; Dietary Supplement: Nestl é BOOST Plus Sponsors: Columbia University; University of California, Berkeley Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials